Leerink Partnrs Has Weak Estimate for Biogen FY2027 Earnings

Biogen Inc. (NASDAQ:BIIB) – Leerink Partnrs reduced their FY2027 earnings per share (EPS) estimates for Biogen in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of $16.65 per share for the year, down from their previous forecast of $18.00. The consensus estimate for Biogen’s current full-year earnings is $16.43 per share. Leerink Partnrs also issued estimates for Biogen’s FY2028 earnings at $17.85 EPS.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.31. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.43 billion. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The company’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.36 EPS.

A number of other research analysts also recently issued reports on BIIB. Robert W. Baird lifted their price target on Biogen from $294.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, November 15th. Jefferies Financial Group lowered Biogen from a “buy” rating to a “hold” rating and cut their target price for the company from $250.00 to $180.00 in a research note on Monday, December 9th. Citigroup decreased their price target on shares of Biogen from $190.00 to $160.00 and set a “neutral” rating for the company in a research report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. Finally, Barclays reduced their price objective on shares of Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research note on Thursday, October 31st. Sixteen analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $228.80.

Biogen Stock Performance

Shares of BIIB stock opened at $146.23 on Friday. The company’s 50 day moving average is $151.32 and its 200 day moving average is $179.80. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The firm has a market cap of $21.31 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 1.66 and a beta of -0.07. Biogen has a 52-week low of $139.71 and a 52-week high of $251.99.

Institutional Investors Weigh In On Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Inspire Trust Co. N.A. boosted its stake in shares of Biogen by 58.5% in the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock worth $2,113,000 after buying an additional 4,025 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Biogen by 0.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock valued at $6,646,000 after acquiring an additional 111 shares during the period. Centre Asset Management LLC boosted its position in Biogen by 7.7% in the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock worth $7,880,000 after purchasing an additional 3,698 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Biogen by 1.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock worth $176,982,000 after purchasing an additional 12,319 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in shares of Biogen by 3.2% during the 3rd quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock valued at $32,687,000 after purchasing an additional 5,270 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.